Dextrose Injection Market - Size, Share, Outlook, and Forecast till 2026

Dextrose is a form of glucose, which is widely used as an artificial sweetener. Dextrose 5% in water is used as a solution for injections to be administered into a vein through an IV to replace lost fluids and provide carbohydrates to the body.

Dextrose is widely used to treat hypoglycemia, insulin shock, and dehydration. Dextrose has nutritional applications and is used as a nutritional support for patients who are unable to eat due to an illness and injury. Increasing prevalence of hypoglycemia in turn, is expected to boost growth of the dextrose injections market.

Fructose is a natural sweetener found in fruits, while dextrose is artificially made for enhancing the taste of varied food products such as honey and sweets. Increasing demand for honey and honey-based products in turn, is increasing the demand for dextrose.

Injections of dextrose are associate severe burning, pain, and swelling around the needled area, furthermore, warmth, redness, oozing, or bleeding where the IV is placed, as well as other health issues such as fever and an ongoing cough. These health issues in turn, pose as major factors hampering growth of the dextrose injections market.

These injections could cause anxiety, sweating, pale skin, severe shortness of breath, wheezing, pain, fast or uneven heart rate, while less severe side effects include upset stomach and swelling in hands or feet. This also poses as a major restraint for growth of the dextrose injections market.

Dextrose Injections USP are sterile, nonpyrogenic, and contain no bacteriostatic or antimicrobial agents. These injections are used for adults and pediatric patients as sources of calories and water for hydration. Dosage depends upon age, weight, and clinical condition. The wide category of usage of these injections are responsible for the rapid growth of the dextrose injections market.

Weifang Shengtai supplied Kelun Pharmaceutical, a pharmaceutical group has 16 subsidiaries with 10 thousand tons of dextrose monohydrate injection grade. Such large scale production by increasing number of manufacturers in turn, is boosting growth of the dextrose injections market.

In June 2018 Amphastar Pharmaceuticals, Inc., announced approval from the U.S. Food and Drug Administration (FDA) for Isoproterenol Hydrochloride Injection, USP 0.2mg/mL, 1mL and 0.2mg/mL, 5mL single dose vial. Isoproterenol Hydrochloride is indicated for multiple uses including for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. Amphastar’s newly approved product was determined by the FDA to be therapeutically equivalent to Isuprel (Isoproterenol Hydrochloride Injection) sold in the U.S. by Valeant Pharmaceuticals.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

1001 4th Ave,
#3200
Seattle, WA 98154,
U.S

This release was published on openPR.